ABU DHABI, UAE, Aug. 30, 2024 /PRNewswire/ — Ferrari World Yas Island, Abu Dhabi hosted an exclusive preview event on August 29 ahead of the launch of the world’s first Ferrari-themed Esports Arena which is set to officially open to the public in September 2024. The award-winning theme park celebration featured VIPs, media, influencers, and other distinguished guests.

To view the Multimedia News Release, please click:  
https://www.multivu.com/players/uk/9287851-ferrari-world-yas-island-hosts-preview-event-ahead-launch-ferrari-themed-esports-arena/

The launch event had guests on the edge of their seats with thrilling live entertainment. Now, F1 fans and adrenaline junkies can immerse themselves in the ultimate racing experience at the Ferrari-themed Park. The arena boasts 20 Gran Turismo simulators, including 14 for adults and 6 designed for younger guests, ensuring fun for the whole family. Adding a further element of thrills, there are three F1 simulators that allow participants to feel the rush of driving a real Ferrari race car on a F1 Grand Prix circuit. Additionally, Ferrari World Abu Dhabi remains committed to inclusivity with two GT simulators specifically designed to accommodate people of determination.

Theme Park entry tickets include access to the GT simulators until year end, while the F1 simulators are available at an additional fee starting from AED 60 per race.

For more information please visit: www.ferrariworldabudhabi.com.

About Ferrari World Yas Island, Abu Dhabi:

Ferrari World Yas Island, Abu Dhabi, the award-winning Ferrari-inspired theme park operated by Miral Experiences, opened its doors to fans in 2010. The theme park celebrates the spirit of the legendary marque and is home to numerous thrilling rides, family-friendly attractions, state-of-the-art simulators, live shows, as well as popular seasonal events and festivities that bring together extraordinary performances from around the globe. Ferrari World Yas Island, Abu Dhabi is home to the world’s fastest roller coaster, Formula Rossa, as well as record-breaking roller coaster Flying Aces and the most immersive mega-coaster Mission Ferrari.

In 2020, Ferrari World Yas Island, Abu Dhabi launched the all-new Roof Walk experience for guests seeking a thrilling adventure. Additionally, the Park welcomed the state-of-the-art Family Zone. Designed to entertain guests of all ages, the Family Zone features four miniature versions of the theme park’s most iconic, record-breaking rides for the entire family to enjoy.

Since its inception, Ferrari World Yas Island, Abu Dhabi has been recognized by several leading industry awards garnering over 60 regional and international accolades. Most recently, the park was named ‘World’s Leading Theme Park’ for the fifth consecutive year by the World Travel Awards and Mission Ferrari won the title of ‘Thrills’ at the 2023 Blooloop Innovation Awards along with ‘Best Theme Park” at the 2023 MENALAC Awards and won a Gold Stevie Award in 2023.

For more information, please visit: www.ferrariworldabudhabi.com

Ferrari World Esports Arena

Source

HONG KONG, Aug. 30, 2024 /PRNewswire/ — ICZOOM Group Inc. (Nasdaq: IZM) (the “Company” or “ICZOOM”), a B2B electronic component products e-commerce platform, announced that ICZOOM Participated in ELEXCON 2024 Shenzhen International Electronics Exhibition and Achieves a Successful Conclusion.

From August 27th to 29th, the ELEXCON 2024 Shenzhen International Electronics Exhibition grandly opened at the Shenzhen Futian Exhibition Center. More than 400 exhibitors participated in the exhibition. With meticulous preparation, ICZOOM attracted numerous customers to the site for consultation and negotiation, and many overseas customers also came to the site to understand our platform. Many visitors to the exhibition showed great interest in the ICZOOM. At this exhibition, ICZOOM made a comprehensive introduction and promotion to the visiting customers, attracting global traffic, and received many inquiries and intent orders, achieving good exhibition results and discovering many potential customers.

At the same time, we also invited original electronic component factory customers to our exhibition hall to share industry knowledge and related company products with us through live broadcasting.

Through this exhibition and live broadcast, both parties have gained a deeper understanding, strengthened existing cooperative relationships, and brought new opportunities for the further development of the ICZOOM.

About ICZOOM Group Inc.

ICZOOM Group Inc. (Nasdaq: IZM) is primarily engaged in sales of electronic component products to customers in Hong Kong and mainland China through its B2B e-commerce platform. These products are primarily used by China based small and medium-sized enterprises (“SMEs”) in the consumer electronic industry, Internet of Things (“IoT”), automotive electronics and industry control segments. By utilizing latest technologies, the Company’s platform collects, optimizes and presents product offering information from suppliers of all sizes, all transparent and available to its SME customers to compare and select. In addition to the sales of electronic component products, the Company also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance. For more information, please visit the Company’s website:
http://ir.iczoomex.com/index.html.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “should,” “will,” “could” and similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

Source: ICZOOM Group Inc.

Source

SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the “Group”) announced the consolidated results for the six months ended 30 June 2024 (the “Reporting Period”).

• International business achieved sustained rapid growth: The revenue of the Group was approximately RMB652.8 million during the Reporting Period, representing a year-on-year growth of approximately 2.1%. Overseas sales of the Group increased by approximately 29.8% as compared with the corresponding period of 2023, has maintained sustained rapid growth, showing the sound and fast development of the international business of the Group.
• Stable profitability: Gross profit of the Group increased by approximately 2.1% year-on-year to approximately RMB515.4 million for the six months ended 30 June 2024. Gross profit margin was approximately 78.9%, being the same with the corresponding period of 2023. Excluding non-recurring items^[1], net profit attributable to owners of the Company was approximately RMB233.6 million, and the net profit margin attributable to owners of the Company was approximately 35.8%, fully demonstrating the Company’s consistently stable profitability.

International Business Achieved Significant Growth, Domestic Market Solidified Foundation for Development

In the first half of 2024, the Company steadfastly pursued its mission to meet unmet clinical treatment needs worldwide through a strategic lens focused on innovation and global outreach. During the Reporting Period, the Group has showcased its commitment by rolling out a rich product portfolio of cutting-edge technology and premium academic services, alongside the synergistic amalgamation of its expertise in branding, patents, distribution networks, clinical trials, market registration, and management of global operations. With the effective implementation of the internationalization development strategies, the Group’s international business has maintained sustained rapid growth. The revenue generated from overseas market of the Group increased by approximately 29.8% as compared with the corresponding period of 2023, which accounted for about 24.9% of the total revenue. Meanwhile, Asia (excluding China’s mainland) and Europe were the two largest overseas market of the Group, which accounted for approximately 10.9% and 10.0%, respectively.

China’s mainland remained the foundation and the largest market of the Group. During the Reporting Period, the domestic sales of the Group decreased by approximately 4.7% as compared with the corresponding period of 2023, which accounted for approximately 75.1% of the total revenue. The Group’s key products, including congenital heart disease (CHD) occluders, left atrial appendage (LAA) occluders, aortic stent grafts, and vena cava filters, have various innovation generations, maintaining the leading position in China market with wide market coverage and sound development foundation. Meanwhile, the Group took more healthy, solid and sustained business development strategies, continuously facilitating the clinical registration and commercialization of new products to actively address the changes and challenges arising in the market and the industry.

Core Business Demonstrated Development Resilience

Structure Heart Diseases (SHD) Business

The products offer by the Group in the SHD business mainly include CHD occluders and LAA occluders. The turnover contributed by the SHD business for the six months ended 30 June 2024 was approximately RMB271.2 million, representing an increase of approximately 11.2% as compared with the corresponding period of 2023. The revenue generated from the sales of LAA occluders increased by approximately 16.0%. This novel device is the Chinese branded LAA occluders with the largest market share among domestic peers in the global market. The Group is currently selling three generations of CHD occluders, aiming to satisfy various market needs through its differentiated product strategies. During the Reporting Period, the revenue generated from the sales of CHD occluders increased by approximately 6.4% as compared with the same period of 2023. The Group has a diversified product portfolio in the treatment of SHD, and continuously catering the increasing clinical needs both domestically and internationally through technology innovation and product upgrades, to further refine the sales layout in the global market.

Peripheral Vascular Diseases (PVD) Business

The Group provides global patients with technology-leading comprehensive interventional medical devices treatment of PVD, including vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts and iliac artery bifurcation stent grafts. During the Reporting Period, the turnover contributed by the PVD business was approximately RMB380.7 million, representing a growth of approximately 5.0% as compared with the same period of 2023. Among these products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. The revenue generated from the sales of stent grafts and vena cava filters increased by approximately 5.1% and 0.9% year-on-year, respectively. The current marketed products together with pipeline products of the Group’s PVD business is expected to provide patients with unprecedented complete endovascular solutions, which could bring the Group with a long-term competitive edge in the treatment of PVD in the global market.

Cardiac Pacing and Electrophysiology (CPE) Business

The Group is the first domestic manufacturer in China which has a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions. During the Reporting Period, the turnover contributed by the CPE business was approximately RMB0.9 million, representing a year-on-year decrease of approximately 97.3%. The decrease was mainly due to the relocation of the pacemaker production line, which required re-validation of equipment and mandated a quality system assessment before the resumption of production. The Company’s implantable cardiac pacemaker compatible with magnetic resonance imaging (“MRI”) is in the domestic registration stage, which will enrich the product portfolio of the Group’s CPE business.

Innovation at the Core to Build Long-term Competitiveness

Independently developed innovative medical device products could maintain the long-term competitive strengths of the Group to support its solid and sustained development. With a robust lineup of products currently ongoing research and development, as well as under clinical trial process, the Group is at the forefront of innovation, boasting products with substantial growth potential and broad market appeal. The strategic approach makes the Group could able to overcome future challenges head-on in the healthcare industry and benefit from its independent innovation in the long run. During the Reporting Period, research and development expenses of the Group was approximately RMB139.9 million, and the Group have achieved the following milestones: 

Product Commercialization in Progress

• DiAcu™ Single Use Endobronchial Ultrasound Aspiration Needle and Distal Access Catheter Kits have obtained the National Medical Products Administration (“NMPA”) certification;
• HeartR™ PDA Occluder, Cera™ PDA Occluder and CeraFlex™ PDA Closure System have obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;
• Aortic Stent Graft System (consists of the Ankura™Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter), Futhrough™ Endovascular Needle System, Balloon Guided Catheter, Affistent™Tracheal Stent System, Disposable Vacuum Aspiration Pump and Intracranial Aspiration Catheter are pending registration approval in China;
• Fitaya™Vena Cava Filter System is under registration approval of CE certification;
• Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™Thoracoabdominal Aortic Stent Graft System, SilverFlow™PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System) have completed its one-year clinical follow-up in China and are working on the clinical summary report;
• CS™ Concave Supra-arch  Branched Stent-Graft System, Cera™ PFO Occluder and Cinenses™ Lung Volume Reduction Reverser System are currently at the stage of the pre-registration clinical enrollment in China;
• X-Clip™ Mitral Value Clip System and X-Clip™ Steerable Guide System are at the stage of the pre-registration clinical preparation in China;
• IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in Europe, its CE registration application has been submitted; and
• IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System of the phase II and III clinical study are at the stage of the clinical follow-up, and its CE registration application has been submitted.

Intellectual Property Rights

Intellectual property is an internal driving force to improve our core competitiveness in the medical device market. As at 30 June 2024, the Group had filed a total of 2,198 valid patent applications, of which 1,008 patents were registered and valid.

The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:

In the first half of 2024, our steadfast commitment in research and development, network expansion, production and quality control, as well as internal management ensured a stable business operation, and further solidified our market foundation, demonstrating a strong resilience for development. Especially, we achieved a sustained rapid growth in the overseas market, making the internationalization level of our business ahead of domestic peers.

Looking ahead, we will continue to focus on the two core development strategies of innovation and internationalization, and leverage innovation to invigorate the robust business dynamics in the global market. We could benefit from the promising growth opportunities in the global market, and the company is expected to occupy a higher market share in the future, providing more and more patients around the world with our novel devices and related therapies. Simultaneously, LifeTech intends to proactively identify and capture new opportunities for development, integrate and leverage beneficial resources from both inside and outside of the Company, to expedite the attainment of our strategic ambitions in the global healthcare industry, creating greater value for patients, doctors, shareholders, and other stakeholders.

About LifeTech Scientific Corporation:

Established in 1999 in Shenzhen, China, LifeTech Scientific Corporation (Stock Code: 1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The Company provides patients with innovative solutions in the treatment of structural heart diseases, peripheral vascular diseases, and bradycardia, and the Company also expands its business scope in respiratory interventional business and neuro interventional business. Moreover, the Company has the world-first innovative iron-based bioabsorbable material technology platform. With the core strategy of innovation and internationalization, the market share of main products of the Company are keeping leading position in the home country, and the Company has established 7 subsidiaries outside mainland China, with network penetration in nearly 120 countries and regions around the world.

Source

• European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients.^[1-3] The safety profile is consistent with that observed in the approved metastatic melanoma indication.^[1]
• The approval follows a positive opinion issued on July 25 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)

CASTRES, France, Aug. 30, 2024 /PRNewswire/ — Pierre Fabre Laboratories announced today that the European Commission (EC) has approved BRAFTOVI^® (encorafenib) in combination with MEKTOVI^® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF^V600E mutation. The approval is based on the results from the Phase II PHAROS trial, a global, open-label, multicentre, non-randomised trial to determine the efficacy and safety of BRAFTOVI^® + MEKTOVI^® in treatment-naïve and previously treated patients with BRAF^V600E mutant metastatic NSCLC.^[1]

“We are pleased to be able to extend the treatment of BRAFTOVI^® (encorafenib) in combination with MEKTOVI^® (binimetinib) to adult patients with advanced NSCLC with a BRAF^V600E mutation in Europe” said Eric Ducournau, Chief Executive Officer of Pierre Fabre Laboratories. “There are currently limited targeted treatment options for BRAF^V600E mutant NSCLC patients, so this approval is a significant milestone as BRAFTOVI^® + MEKTOVI^® will give patients the option of an additional effective targeted therapy.”

The EC decision, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on 25 July, is based on the results from the Phase II PHAROS trial.^[1-3] At primary analysis (cut-off date: September 22, 2022), the primary endpoint of the trial (objective response rate [ORR] determined by independent radiology review [IRR]) was met. In the treatment-naïve population (n=59), the ORR was 75% (95% CI: 62, 85), including 15% complete responses (CRs) and 59% partial responses (PRs).^[1-3] Updated results with an additional 10-month follow-up showed that 64% of patients maintained a response for at least 12 months, with a median duration of response (mDOR) per IRR of 40 months (95% CI: 23.1, not estimable [NE]).^[2,3]*

CONTACT: Laurence MARCHAL, laurence.marchal@pierre-fabre.com

PDF – https://mma.prnewswire.com/media/2493339/Pierre_Fabre_Approval.pdf

Source

BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH).

According to the terms of the agreement, Jacobio shall receive around RMB200 million in the near term, which includes an upfront payment of RMB150 million, and around RMB50 million of compensation for research and development expenses and other payments. Additionally, the potential milestone payments upon achieving certain development, regulatory and commercial milestones are up to RMB700 million. Jacobio is also entitled to receive tiered double-digit royalty payments on net sales of glecirasib and JAB-3312 from Allist, among which the royalty payments on net sales of JAB-3312 is up to 20%. The above amount includes value-added tax. Allist will be responsible for the commercialization of glecirasib and JAB-3312 in China and pay the subsequent clinical development costs in China. This marks that Jacobio has officially entered the commercialization stage, and the research and development of SHP2 has also ushered in a new milestone.

Dr. Wang Yinxiang, Chairman and CEO of Jacobio, said: “We are delighted to reach this cooperation with Allist. Allist has strong commercialization capabilities in the field of lung cancer, and the first indication for glecirasib submitted the new drug application is lung cancer. We believe that with the deep fit of the advantages of both parties, this collaboration will demonstrate great clinical and commercial value. In addition to the cooperation with glecirasib, Allist also licensed-in the SHP2 inhibitor JAB-3312, which is the first SHP2 inhibitor entering a registrational trial globally. It is expected to become a first-line therapy in combo with glecirasib, which reflects Allist’s foresight into the future of pipelines. We also look forward to jointly accelerating the development and commercialization of the two products to meet the clinical needs of more patients. “

Jinhao Du, the Chairman and general manger of Allist, said: “we are please to cooperate  with Jacobio, and the cooperation will surely benefit the growth of both companies. For many years, Allist has taken ‘Technology Cares for Life’ as our corporate mission, focusing on scientific exploration and drug development in the field of cancer therapies, and is committed to developing and introducing superior pipelines consisting of best-in-class and first-in-class drugs. While we successfully independently developed and launched furmonertinib, we have built a commercial team that focuses on lung cancer, has professional academic promotion capabilities, and has a wide sales channel coverage. Since its launch, furmonertinib has achieved remarkable sales performance. Jacobio is a very outstanding innovative biotech company that has successfully developed and promoted a number of excellent products with great clinical value, including the KRAS G12C inhibitor glecirasib and the SHP2 inhibitor JAB-3312. We are very optimistic about the clinical advantages and market prospects of these two products. In this cooperation, Allist will give full play to its advantages in clinical development and commercialization capabilities to benefit more Chinese patients and create value for both companies.”

The new drug application for glecirasib monotherapy for second-line non-small cell lung cancer (NSCLC) with KRAS G12C mutation was granted priority review on May 21, 2024. In December 2022, it was granted breakthrough therapy designation (BTD) Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the second-line and above treatment of patients with advanced or metastatic NSCLC with KRAS G12C mutation. In April 2024, the data of the pivotal Phase II study of glecirasib published by Jacobio in the ASCO Plenary Series showed that in patients with second-line NSCLC, the confirmed objective response rate (cORR) was 47.9% (56/117), including 4 patients achieved a complete response (CR) and 36 patients with tumor reduction exceeding 50%. Disease control rate (DCR) was 86.3%. The median progression-free survival (mPFS) was 8.2 months, and median overall survival (mOS) was 13.6 months.

The first patient dosed in the Phase III clinical trial of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 versus standard care (chemotherapy and anti-PD-1 antibody) in front-line KRAS G12C mutant NSCLC in August 2024. According to the Phase I/IIa data presented at the ASCO Annual Meeting, the optimal dose group was glecirasib at 800mg daily combined with JAB-3312 at 2mg daily one week on and one week off. The cORR of the optimal dose group was 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data, among the 194 all-dosage patients, the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable.

In addition, the pivotal studies of glecirasib monotherapy for second-line or above pancreatic cancer, glecirasib monotherapy and in combination with cetuximab for colorectal cancer with are also undergoing. In terms of pancreatic cancer, in April 2024, glecirasib was granted orphan drug designation from Food and Drug Administration (FDA) for pancreatic cancer indications; in August 2023, it was granted BTD by CDE of NMPA for the treatment of second-line or above pancreatic cancer patients with KRAS G12C mutations. The combination of glecirasib and cetuximab for the treatment of colorectal cancer was approved for registrational phase III clinical trial in China in May 2024.

About Glecirasib
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China.

About JAB-3312
JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor glecirasib has been approved by China CDE in Feb 2024.

About Jacobio
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.

About Allist
Shanghai Allist Pharmaceuticals Co., Ltd, founded in March, 2004, is an innovative pharmaceutical company with a fully integrated system for research and development, manufacturing, and commercialization of novel oncology drugs with a purpose to meet with medical needs across the globe. In accordance with its development concept “Advancing Long Life with Innovation of Science and Technology”, Allist is dedicated to self-develop First-in-class and Best-in-class drug candidates. After 20 years of endeavor, Allist has successfully developed and received approvals of two innovative drugs by its own. On December 2nd, 2020, Shanghai Allist Pharmaceuticals Co., Ltd. was officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock number: 688578).

Source